Search

Search Constraints

You searched for: Author/Creator Garufi, S

Search Results

1. P288 Vedolizumab May Be An Effective Option For The Management Of Postoperative Recurrence Of Crohn's Disease. (27th May 2021)

2. P305 Effectiveness and Safety of Vedolizumab in Biologic-Naïve Patients: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). (27th May 2021)

3. P325 A propensity score-weighted comparison of vedolizumab and adalimumab in Crohn's disease: Real-life data from the Sicilian Network for inflammatory bowel disease (SN-IBD). (15th January 2020)

4. P345 The Effectiveness of Ustekinumab and Vedolizumab as Third-line Therapy in Patients with Refractory Crohn's Disease. (21st January 2022)

5. P436 SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501. (27th May 2021)

6. P439 Effectiveness of Ustekinumab on Crohn's disease associated spondyloartropathy: real-world data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). (27th May 2021)

7. P545 Elderly patients with inflammatory bowel disease (IBD) are less likely to persist on anti-TNF therapy compared with younger patients: data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). (25th January 2019)

8. P737 SPOSIB SB2: A Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab Biosimilar SB2 (Flixabi®): interim analysis. (25th January 2019)